News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model
Telomir-1 reverses tremors, ataxia, liver & kidney damage in Wilson's disease animal model, showing regenerative potential across genetic disorders -
-
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Swissnet AG (formerly Beaconsmind AG) (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research reaffirms BUY rating for Swissnet AG (formerly Beaconsmind AG) with a target price of €18.50 after strong FY/24 results & positive outlook for FY/25. Organic revenue grew 25% and adj. EBITDA grew 438%